McKesson Corporation (NYSE:MCK) is one of the the best-performing S&P 500 stock over the past five years.

On February 5, 2026, BofA reaffirmed its “Buy” rating on McKesson Corporation (NYSE:MCK) and raised its price target from $950 to $970. Calling the third quarter strong, the firm pointed to revenue and EPS, both beating Street expectations. Citing the solid performance of the US pharmaceutical segment and the continued strength of the oncology and multispecialty segment, BofA raised its FY26 and FY27 EPS projections.

The analyst update followed McKesson Corporation’s (NYSE:MCK) third-quarter earnings and outlook update on February 4, 2026, in which the company raised its 2026 adjusted EPS forecast from a previous range of $38.35-$38.85 to $38.80-$39.20.

Also, McKesson Corporation (NYSE:MCK) reported third-quarter revenue of $106.16 billion, beating the forecast of $105.86 billion, and adjusted EPS of $9.34, beating the forecast of $9.22. Demand for specialty drugs and strong prescription volumes helped sales in the US pharmaceutical segment increase 9% to $88.3 billion.

McKesson Corporation (NYSE:MCK), a healthcare services company, provides pharmaceutical distribution, specialty drug solutions, prescription technology services and medical-surgical supplies in the United States and international markets.

While we recognize MCK’s potential as an investment, we believe some AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from the Trump-era tariffs and onshoring trend, check out our free report on the best short-term AI stock.

READ THE FOLLOWING: What are the best stocks to buy right now? i 10 Stocks Under $1 That Will Explode.

Disclosure: none